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also studied. She was a secretor of both A and H blood groupntroduction
he ABH antigens are histo-blood group antigens that are
resent in circulating blood cells, tissues and body ﬂuids.
he association of blood groups with various disease states
as been well documented in the literature. Both hematopoi-
tic and non-hematopoietic malignancies are associated with
lood group changes. In solid organ malignancies, excessive
lood group substances produced by the tumor lead to blood
roup discrepancies.1 However, such discrepancies are rare
ith a very few case reports in the literature. Herein, we
escribe an unusual case of a blood group discrepancy in a 48-
ear-old lady who  was diagnosed with signet ring cell gastric
denocarcinoma.
ase  description
 blood sample of a 48-year-old lady was received for blood
rouping and cross-matching. Her hemoglobin, total leuko-
yte and platelet counts were 5.6 g/dL, 4800 cells/L and
.84 × 105 cells/L, respectively. As per our protocol, we did
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pen  access article under the CC BY-NC-ND license (http://creativecomthe preliminary blood grouping of the patient with unwashed
cells using the tube technique to check availability of blood
in our inventory. Forward grouping results were as follows:
no agglutination with anti-A and anti-B antisera and, weak
agglutination with anti-A,B monoclonal antiserum. Reverse
grouping revealed A group. The results were similar with a
repeat sample and column agglutination technology. Reac-
tion with anti-A1 lectin was negative and reaction with anti-H
lectin was 4+. The initial blood grouping was mimicking the Ax
phenotype. As per her previous blood group records, she was
A Rh D positive. The patient had a history of transfusion ﬁve
years previously during a hysterectomy. The blood grouping
was repeated after washing her red cells thrice with physiolog-
ical saline (0.9%) as per the departmental standard operating
procedure. Strong agglutination was noted with anti-A and
anti-A,B (Figure 1). Reaction with anti-A1 lectin was positive
and reaction with anti-H lectin was 4+. Hence, her blood group
was conﬁrmed as A1 Rh D positive. Saliva secretor status wasda Hospital, Malakpet, Hyderabad 500036, India.
substances.
Meanwhile, we gathered details of the patient’s medical
history. The patient was admitted two months previously
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Strong agglutination
with anti-A after
washing
Noagglutination
with anti-A before
washing
Figure 1 – Unwashed red cells of the patient showed no
agglutination with monoclonal anti-A, while after washing
three times, red cells showed strong agglutination with
anti-A.
with a history of abdominal pain. Multislice spiral computed
tomography (CT) of the abdomen revealed a heterogeneously
enhanced transmural wall thickening (3.5 cm)  with a large
ulcer and irregular mucosa in the gastric fundus and body.
The mass was invading the left adrenal gland. There was
no associated lymphadenopathy or distant metastasis. These
ﬁndings were consistent with a diagnosis of locally advanced
gastric cancer. Upper gastrointestinal endoscopic biopsy con-
ﬁrmed the diagnosis of a primary gastric signet ring cell
carcinoma. She completed two cycles of 5-ﬂurorouracil and
cisplatin-based palliative chemotherapy. The present blood
sample was taken three weeks after the second cycle of
chemotherapy.
We suspected that there might be A blood group substance
in the patient’s serum which inhibited the reaction with anti-A
antiserum. The amount of inhibiting substance in the patient’s
serum was tested based on the methodology described by
Treacy et al.2 Monoclonal anti-A was titrated against A2 cells.
The titer of anti-A was 1:512 and a dilution of 1:16 was used for
the study (the next to the last dilution showing a 4+ reaction
with A2 cells was used). A2 cells were prepared from a sin-
gle donor. Doubling dilutions of serum (each tube containing
100 L of the patient and a healthy blood group A donor) was
made and 100 L of diluted monoclonal anti-A was added to
each tube. The suspensions were mixed well and incubated for
30 min  at room temperature. An aliquot of 100 L of washed
A red cells was added to all tubes, incubated at room tem-
perature for 30 min  and centrifuged at 1000 rpm for 1 min.
Complete neutralization (inhibition of hemagglutination) was
seen up to 1:64 dilution of the patient’s serum, while normal
control serum showed no inhibition. Hence, it was concluded
that the blood group discrepancy noted in this patient was due
to the presence of an excess of A blood group substance in her
serum, probably secreted by the tumor cells. The patient was
transfused with one unit of A1 Rh D positive packed red blood
cells and the transfusion was uneventful. Her post-transfusion
hemoglobin was 7 g/dL. She was followed-up for three weeks
after chemotherapy. There was no apparent reduction in neu-
tralization activity of the serum.
DiscussionSeveral studies in the past have reported on malignancies
and their effects on blood groups. Other than red cells, spe-
ciﬁc substances of ABH blood groups have been detected
in mucous glands, epithelial cells, neurons, and vascular 2 0 1 6;3  8(4):361–363
endothelial cells.3,4 Alterations of red cell antigens occur with
both hematologic and solid malignancies. In hematological
malignancies, loss/weakening of red cell antigen expression
occurs due to genetic and epigenetic changes in the A and
B transferase genes. In solid tumors (bladder, lung, head and
neck, cervical, and thyroid), loss of expression of the histo-
blood group ABH antigens from tumor cells is a known event,
but red cell antigen expression may not be reduced.5 Rather,
neutralization of typing antiserum by the blood group-speciﬁc
soluble substances secreted by tumor cells can be seen.1
The ﬁrst report of such association was in 1959 when Bar-
ber and Dunsford reported excess of blood group A substance
in a female patient with gastric carcinoma resulting in a
blood group discrepancy.6 This ﬁnding has also been reported
to occur in pancreatic, ovarian, colonic, and bile duct car-
cinoma and, pseudomucinous ovarian cysts.1,7,8 Secretions
from tumor cells enter the blood stream either directly or
through ascitic ﬂuid absorption.8 Saeed and Fine demon-
strated excess A and H blood group substances in tumor
cell cytoplasm by immunoﬂuorescence studies in a patient
with stomach adenocarcinoma. These excess soluble antigens
probably neutralized anti-A antiserum that led to ambiguous
blood grouping.9 Rouger et al. studied 70 patients with gas-
tric or colon carcinoma and concluded that the individuals of
blood group A had higher levels of A blood group substance
in serum when compared to controls,10 however the reason
for this biochemical behavior is not known. Joshi et al. from
India reported a case of blood group discrepancy due to excess
secretions of A blood group substance by ovarian mucinous
cystadenoma. After resection of the tumor, the discrepancy
was reversed.11 Unusually, blood group substances have been
found in healthy individuals and even at lower concentrations
in newborns.6,8,9
ABH blood group substances neutralize the commercial
antiserum providing no binding site for red cell antigens. Com-
plete washing of red cells removes the inhibiting substance
unmasking the effect. In our case, complete inhibition was
seen up to 1:64 dilution of the patient’s serum. In a series
of four patients, Treacy et al. noted high concentrations of
A blood group substance in serum with titers ranging from
1:512 to 1:2048, whereas Joshi et al. reported hemagglutina-
tion inhibiting activity of A blood group substance only up to
a 1:128 dilution.2,10
Loss of ABH antigens from the dedifferentiated tumor
cells is also known and has been associated with a nega-
tive prognostic impact. It is evident from the literature that
most of the patients with carcinoma who were reported
to have this neutralization effect in serum were diagnosed
with end stage/advanced disease and later succumbed to
the disease.2,6,9 Although this statement seems quite sim-
ple, some questions still remain unanswered. (1) Is excess
of blood group substances in serum related to tumor clini-
cal behavior and prognosis? (2) Is the ﬁnding of excess blood
group substances more  common in adenocarcinomas of the
gastrointestinal tract and ovaries than tumors at other sites?
Further exploration is needed to comment on these questions.
Notwithstanding, rapidly expanding molecular diagnostics,
serological methods undoubtedly have a ﬁrst-line role to
solve blood group discrepancies in the practice of transfusion
medicine.
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We  conclude that excess blood group substances in the
erum neutralizing the typing antiserum is a very rare phe-
omenon. This has been demonstrated in patients with
astrointestinal tract carcinoma and ovarian cysts. Serologi-
al techniques would be helpful in resolving these blood group
iscrepancies where molecular methods are unavailable espe-
ially in resource-limited settings.
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